Therapeutic groups
Gross spend in millions
Therapeutic group | Main indication | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|
1 |
Immunosuppressants |
Autoimmune conditions and cancer |
$361.3 |
$396.0 |
$374.9 |
$440.2 |
2 |
Vaccinations |
Vaccine preventable diseases including COVID-19 |
$113.9 |
$112.0 |
$130.1 |
|
3 |
Diabetes |
Diabetes |
$91.8 |
$123.7 |
$148.3 |
$173.2 |
4 |
Chemotherapeutic agents |
Cancer |
$137.7 |
$148.9 |
$154.2 |
$158.0 |
5 |
Mucolytics |
Cystic fibrosis |
$4.7 |
$14.1 |
$44.3 |
$130.3 |
6 |
Antivirals |
Hepatitis C and COVID-19 |
$61.3 |
$42.2 |
$54.5 |
|
7 |
Antifibrinolytics, Haemostatics and Local Sclerosants |
Haemophilia |
$54.7 |
$58.8 |
$60.6 |
$90.6 |
8 |
Inhaled long-acting beta-adrenoreceptor agonists |
Respiratory conditions |
$67.4 |
$75.6 |
$74.2 |
$75.8 |
9 |
Antithrombotic agents |
Stopping blood clots |
$86.2 |
$96.5 |
$104.7 |
$57.0 |
10 |
Multiple sclerosis treatments |
Multiple sclerosis |
$39.3 |
$44.0 |
$50.1 |
$52.9 |
11 |
Agents Affecting the Renin-Angiotensin System |
Heart failure and high blood pressure |
$22.1 |
$31.7 |
$39.1 |
$49.5 |
12 |
Endocrine Therapy |
Cancer |
$47.8 |
$43.7 |
$40.7 |
$43.0 |
13 |
Antipsychotics |
Mental health |
$37.2 |
$38.5 |
$40.8 |
$42.2 |
14 |
Anticholinergic Agents |
Respiratory conditions |
$31.4 |
$33.3 |
$35.0 |
$38.1 |
15 |
Antiretrovirals |
HIV/AIDS |
$26.6 |
$28.2 |
$31.9 |
$34.9 |
16 |
Diabetes Management |
Diabetes |
$26.7 |
$29.4 |
$31.9 |
$34.9 |
17 |
Antiepilepsy Drugs |
Epilepsy and pain relief |
$25.6 |
$29.4 |
$29.7 |
$31.3 |
18 |
Oral and Enteral Feeds |
Nutritional needs |
$20.2 |
$23.5 |
$26.2 |
$29.8 |
19 |
Analgesics |
Pain relief |
$27.5 |
$26.6 |
$27.0 |
$29.6 |
20 |
Stimulants/ADHD Treatments |
ADHD and narcolepsy |
$11.4 |
$13.4 |
$17.0 |
$22.5 |
|
|
Totals |
$1,294.8 |
$1,407.7 |
$1,515.3 |
$1835.2 |
- Medicines purchased by hospitals (worth $145 million in 2023/24) are excluded
- Gross spend is shown in millions NZD, is exclusive of GST, and is prior to the application of rebates and discounts
- Gross spend for 2020/21 to 2022/23 is different to what was reported in previous YIR Top 20 lists as the methodology has been revised due
to an increase in the number and type of medicines funded - The total gross spend for 2023/24 was $2,511 million, and the top 20 therapeutic groups account for 72% of the total
- COVID-19 Treatments and Vaccines were funded from the National Pharmaceutical Purchasing Appropriation from 2023/24
- COVID-19 Treatments and and COVID-19 Vaccines pricing is confidential, and as COVID-19 gross spend is only included from 2023/24, gross
spend for those therapeutic groups is not stated for confidentiality